FRANKLIN LAKES, N.J. (Sept. 24, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement:
Today, the Attorneys General from 48 states and the District of Columbia announced a $60 million settlement with BD to resolve legacy litigation from C. R. Bard that was initiated prior to BD’s acquisition in 2017 and related to discontinued pelvic mesh products.
Ensuring the safety and quality of our products has always been the top priority at BD. In addition, BD fully complies with all laws and regulations for the medical products the company manufactures, markets and distributes. Bard and BD have denied any wrongdoing and all allegations included in the litigation and chose to settle the matter to avoid the time and expense of further litigation.
BD is fully reserved for the settlement amount.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.